A new weight-loss drug is superior to the "Ozembic" injection in burning fat

null
Scientists have developed a new weight-loss drug that could make patients lose twice the amount of fat they achieved with current popular medications, such as Ozempic.

According to the results of the experiments, obese patients who received the injection once a week lost approximately 19% of their body weight, on average, after five and a half months of treatment.

For comparison, a number of trials have shown that Semaglutide injections, which are sold under the brand names Ozempic, Wegovy, and Rybelsus, lead to a 10% reduction in body weight. Approximately after six months of use.

Furthermore, the results found that those with prediabetes who took the new drug went into remission (a period in which symptoms are absent) by the end of the trial.

The study data, which was revealed by the giant Swiss pharmaceutical company Roche on Thursday, shows that the rate of side effects is similar to the rate of other currently available injections.

Side effects included mild to moderate gastrointestinal effects such as nausea and vomiting.

The drug, called CT-388, was tested in a phase 1 trial designed to check whether the drugs are safe for human use.

The study included 31 obese adults who did not suffer from any underlying diseases, including type 2 diabetes.

A separate trial is scheduled to test the drug on diabetics.

At week 24, results showed that 45% of participants lost more than 20% of their body weight. All participants lost at least 5% of their weight.

Ozempic and Wegovi injections work by mimicking high levels of natural hormones that regulate blood sugar and suppress appetite.

Roche's drug works similarly to the drugs "Terzepatide", which is sold under the brand names "Mounjaro" and "Zepbound", which is manufactured by the pharmaceutical company Eli Lilly.

Unlike semaglutide, terzepatide acts on not one, but two appetite-suppressing hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinopeptide (GIP), both of which induce feelings of satiety. And suppress appetite.

Scientists hypothesized that targeting these two hormones could have a measurable effect on weight loss and blood sugar levels with fewer side effects than drugs that target glucagon-like peptide-1 only.

“We are very pleased to see significant and clinically significant weight loss in people treated with CT-388,” said Dr. Levi Garraway, Roche’s chief medical officer. “The results are very encouraging to further develop CT-388 for both obesity and type 2 diabetes.” "It confirms its potential to become the best-in-class treatment for lasting weight loss and glucose control."

The drug still has a long way to go before it reaches the approval stage, with many additional trials needed to prove its effectiveness. The price of the medicine was also not revealed.